Drugs / CC-92252
last change Aug 2021 re-read 3 minutes ago

CC-92252

Developed for
psoriasis
Investigated by
Celgene Corporation

Trials 1

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03971825 Jul 2018 → Aug 2021 psoriasis Celgene Corporation Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CC-92252 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03971825 ↗